Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: A prospective evaluation

BJU International

Volumn 106, Issue 11, 2010, Pages 1643-1647

  Miyake, Hideaki ^a   Kurahashi, Toshifumi ^a   Yamanaka, Kazuki ^b   Kondo, Yutaka ^b   Takenaka, Atsushi ^a   Inoue, Taka Aki ^b   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO CANCER CENTER   (Japan)

Author keywords

health related quality of life; renal cell carcinoma; sorafenib

Indexed keywords

SORAFENIB;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; EMOTIONAL DISORDER; FEMALE; HAND FOOT SYNDROME; HEALTH STATUS; HUMAN; HYPERTENSION; JAPANESE; KIDNEY CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; METASTASIS; NEPHRECTOMY; OBSERVATIONAL STUDY; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RASH; SCORING SYSTEM; SHORT FORM 36; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; EPIDEMIOLOGIC METHODS; FEMALE; HEALTH STATUS; HUMANS; JAPAN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 78649312166     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09437.x     Document Type: Article

References (22)

1. Eiser C, Penn A, Katz E, Barr R,. Psychosocial issues and quality of life. Semin Oncol 2009; 36: 275 - 80
2. Parton M, Gore M, Eisen T,. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 2006; 24: 5584 - 92
3. Bellmunt J, Montagut C, Albiol S, Carles J, Maroto P, Orsola A,. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int 2007; 99: 274 - 80
4. Lane BR, Rini BI, Novick AC, Campbell SC,. Targeted molecular therapy for renal cell carcinoma. Urology 2007; 69: 3 - 10
5. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835 - 44
6. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125 - 34
7. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S,. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007; 37: 755 - 62
8. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ,. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13: 1084 - 96
9. Bukowski R, Cella D, Gondek K, Escudier B,. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007; 30: 220 - 7
10. Cella D, Li JZ, Cappelleri JC, et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon α: results from a phase III randomized trial. J Clin Oncol 2008; 26: 3763 - 9
11. Castellano D, Del Muro XG, Pérez-Gracia JL, et al. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Ann Oncol 2009; 20: 1803 - 12
12. Trask PC, Bushmakin AG, Cappelleri JC, Bycott P, Liau K, Kim S,. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. Acta Oncol 2008; 47: 843 - 51
13. Cella D,. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer Treat Rev 2009; 35: 733 - 7
14. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K,. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 1998; 51: 1037 - 44
15. Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B,. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998; 51: 1045 - 53
16. Costa-Requena G, Gil F,. Quality of life in the chemotherapy treatment of Spanish cancer patients: a comparison of general population norms. Psychooncology 2009; 18: 1053 - 9
17. Mols F, Van De Poll-Franse LV, Vingerhoets AJ, et al. Long-term quality of life among Dutch prostate cancer survivors: results of a population-based study. Cancer 2006; 107: 2186 - 96
18. Miyake H, Muramaki M, Eto H, Kamidono S, Hara I,. Health-related quality of life after chemotherapy for advanced germ cell tumours: a comparison of standard-dose and high-dose chemotherapy. Int J Urol 2004; 11: 542 - 6
19. Crippa S, Domínguez I, Rodríguez JR, et al. Quality of life in pancreatic cancer: analysis by stage and treatment. J Gastrointest Surg 2008; 12: 783 - 93
20. Wilson TR, Alexander DJ,. Clinical and non-clinical factors influencing postoperative health-related quality of life in patients with colorectal cancer. Br J Surg 2008; 95: 1408 - 15
21. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ,. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 2008; 26: 3770 - 6
22. Gacci M, Lapini A, Serni S, et al. Predictors of quality of life after radical treatment for prostate cancer. Urol Int 2008; 80: 231 - 6